Eosinophilic colitis: Case series and literature review

Arco, Cristina Díaz del; Taxonera, Carlos; Olivares, David; Fernández-Aceñero, María Jesús

doi:10.1016/j.prp.2017.09.029

Cited by 32 publications

(36 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Some studies have demonstrated a male predominance of certain nonesophageal EGIDs such as EC, but in general there appears to be a lack of male predominance in these disorders. [32][33] When evaluating the initial management of these disorders, wide variability existed amongst participating centers, which may speak to differences in provider preference/experience, the lack of high level evidence to support any given therapy, as well as to the heterogeneity of the presentation of these disorders. PPIs were the most commonly used medication, even in patients with colonic disease.…”

Section: Discussionmentioning

confidence: 99%

Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium

et al. 2019

View full text Add to dashboard Cite

Objective: The literature related to eosinophilic gastritis (EG), gastroenteritis (EGE) and colitis (EC) is limited. We aimed to characterize rates of diagnosis, clinical features, and initial treatments of patients with EG, EGE, and EC. Methods: In this retrospective study, data were collected from six centers in the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR) from 2005-2016. We analyzed demographics, time trends in diagnosis, medical history, presenting symptoms, disease overlap, and initial treatment patterns/responses. Results: Of 373 subjects (317 children and 56 adults), 38% had EG, 33% EGE, and 29% EC. Rates of diagnosis for all diseases increased over time. There was no male predominance, and the majority of subjects had atopy. Presenting symptoms were similar between diseases with nausea/ vomiting and abdominal pain the most common. 154 subjects (41%) had eosinophilic inflammation outside of their primary disease location with the esophagus the most common second GI segment involved. Multi-site inflammation was more common in children than adults (68% vs 37%; p<0.001). Initial treatment patterns varied highly between centers. 109 subjects (29%) had follow-up within 6 months and the majority had clinical, endoscopic and histologic improvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In a similar study by Mansoor et al, a similar female predominance was found in both EGE and EC 8 . Some studies have demonstrated a male predominance of certain non-esophageal EGIDs such as EC, but in general there appears to be a lack of male predominance in these disorders 32-33 .…”

Section: Discussionmentioning

confidence: 99%

Increasing Rates of Diagnosis, Substantial Co-occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis and Colitis Based on 10 Year Data Across a Multi-Center Consortium

Pesek

Reed²,

Muir

et al. 2018

Preprint

View full text Add to dashboard Cite

Financial Support and AcknowledgementsSupport for this project was provided through a research training grant as part of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) (U54 AI117804). CEGIR is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and is funded through collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy groups including APFED CURED and EFC. This project also received support from NIH T32 DK007634 (CCR).Author DisclosersPatricia Fulkerson: Grant funding from the NIH; Consultant for Genentech, Inc; Research support from Knopp Biosciences, LLC.Gary Falk: Research support from Shire, Celgene, Adare, Regeneron. Consulting for ShireJonathan M. Spergel: Consultant for Regeneron, DBV Technology, Kaleo; Grant funding from DBV Technology, Aimmune Therapeutics, Food Allergy Research Education; Royalties from UpToDateNirmala Gonsalves: Royalties from UpToDate; Advisory board for AllakosSandeep K Gupta: Consultant for Alkalos, Abbott, QOL, Receptos; research support from ShireGlenn Furuta: Founder of EnteroTrack; Consultant for Shire; Royalties from UpToDateMarc E. Rothenberg: Consultant for Pulm One, Spoon Guru, ClostraBio, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron and Novartis and has an equity interest in the first four listed and Immune Pharmaceuticals, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children’s.Evan Dellon: Consultant for Adare, Allakos, Alivio, Banner, Celgen/Receptos, Enumeral, GSK, Regeneron, Shire; Research funding from Adare, Celegene/Receptos, Miraca, Meritage, Nutricia, Regeneron, Shire, Educational grant from Banner, HoloclaraStudy HighlightsWhat is current knowledge?Eosinophilic gastrointestinal disorders (EGIDs) include eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), gastroenteritis (EGE), and colitis (EC).Non-EoE EGIDs are rare with most studies limited to case reports or review of single center experiences.There are no widely established guidelines for the diagnosis of EG, EGE, or EC.What is new here?In this multicenter study, EG, EGE, and EC were all diagnosed with increasing frequency over the past decade.Presenting symptoms are non-specific and do not reliably distinguish between disorders.There was no male predominance and the majority of subjects had atopy.Co-occurrence of EG, EGE, and EC diagnoses is common, seen in 41% of patients.There is substantial variability between centers in initial treatment approaches.

show abstract

“…Numerous secondary causes of eosinophilic infiltration of the bowel wall have been identified in the literature. These include drugs (clozapine, rifampicin, and naproxen), parasitic infestation, scleredema, polymyositis, vasculitis, inflammatory bowel disease, radiotherapy, lymphomas, and carcinomas [17].…”

Section: Discussionmentioning

confidence: 99%

A Pink Herring in the Colon: A Case Report of Eosinophilic Colitis Masking Invasive Adenocarcinoma of the Colon

Milne

Rattan

Muddeen

et al. 2020

Case Reports in Surgery

View full text Add to dashboard Cite

Eosinophilic colitis is an inflammatory condition in which the wall of the colon becomes infiltrated by eosinophils which stain densely pink on microscopy. It is an uncommon clinical entity which has a long list of differential diagnoses. We present a case of a patient whose biopsy at colonoscopy revealed eosinophilic colitis which led to a delay in the diagnosis and subsequent treatment of colon cancer. A 35-year-old male presented with a six-week history of right lower quadrant abdominal pain associated with diarrhoea and weight loss. Colonoscopy showed an inflamed cecum; computed tomography revealed a small ascitic fluid collection in the right iliac fossa. Biopsy showed eosinophilic colitis, and he was treated conservatively with albendazole and mesalamine. The patient failed to improve over the following month with continued weight loss. A repeat CT scan showed a right iliac fossa mass. A right hemicolectomy was performed with histopathology from the specimen showing mucinous adenocarcinoma. Eosinophilic colitis can mask colon cancer and should be considered a diagnosis of exclusion.

show abstract

Eosinophilic colitis: Case series and literature review

Cited by 32 publications

References 18 publications

Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium

Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium

Increasing Rates of Diagnosis, Substantial Co-occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis and Colitis Based on 10 Year Data Across a Multi-Center Consortium

A Pink Herring in the Colon: A Case Report of Eosinophilic Colitis Masking Invasive Adenocarcinoma of the Colon

Contact Info

Product

Resources

About